ArticleAntimicrobial agents and chemotherapy2019
Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.
Open access · hybridAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- NewTheScientificWorldJournal · 2025Pooled it
- Small-molecule activators of theiScience · 2026Article
- Bioinspired peptide cyclisation enables exploration of cytochrome P450 catalysed sequential oxidation in rufomycin biosynthesis.Chemical science · 2026Article
- ClpC1-dependent iron homeostasis underlies mycobacterial defense against oxygen-driven Fenton reaction during reactivation.Microbiology spectrum · 2026Article
- A Machine Learning-Based Genome Mining Approach Reveals Unprecedented Biarylitide Diversity.JACS Au · 2026Article
- Phosphoarginine modulates oligomerization and repressor activity of mycobacterial ClpC2.bioRxiv : the preprint server for biology · 2026Article
- Review
- High-throughput screening to identify inhibitors of the MTB CARD•RNA polymerase protein-protein interaction.Frontiers in tuberculosis · 2026Article
- Antimycobacterial peptides as natural therapeutics for tuberculosis: mechanisms and structural features.Frontiers in antibiotics · 2026Review
- Assessing Nanopore Targeted Sequencing for the Diagnosis of Pulmonary Infections: A Comparative Multidisease Approach.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance.npj antimicrobials and resistance · 2025Review
- Recycling of Undigested Proteins Provided by the Host to the Large Intestine Microbiota: Implication for Intestinal Bacterial Anabolism, Growth, and Physiology.Microorganisms · 2025Review
- Natural Products with Potent Antimycobacterial Activity (2000-2024): A Review.Molecules (Basel, Switzerland) · 2025Review
- Allosteric regulation of proteolytic machines unveiled by the synergy between cryo-EM and solution NMR spectroscopy.The Biochemical journal · 2025Review
- Mutations in ClpC1 or ClpX subunit of caseinolytic protease confer resistance to ilamycins in mycobacteria.Communications biology · 2025Article
- Total Syntheses of Stereoisomeric Congeners of Rufomycin Natural Products Having Anti-Mycobacterial Activity.Organic letters · 2025Article
- The Identification of Novel Mutations in ATP-Dependent Protease ClpC1 Assists in the Molecular Diagnosis of Obscured Pyrazinamide-Resistant Tuberculosis Clinical Isolates.Microorganisms · 2025Article
- Enhancing rufomycin production by CRISPR/Cas9-based genome editing and promoter engineering inSynthetic and systems biotechnology · 2025Article
- Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2025Review
- Structure-Based Analysis of Semisynthetic Anti-TB Rufomycin Analogues.Journal of natural products · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 2 countries.
Mary P ChoulesInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Nina M WolfInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Hyun LeeDepartment of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Jeffrey R AndersonInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Edyta M GrzelakInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Yuehong WangInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Rui MaInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Wei GaoInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
James B McAlpineInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Ying-Yu JinCenter for Nutraceutical and Pharmaceutical Materials, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea.
Jinhua ChengDivision of Bioscience and Bioinformatics, College of Natural Science, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea.
Hanki LeeCenter for Nutraceutical and Pharmaceutical Materials, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea.
Joo-Won SuhCenter for Nutraceutical and Pharmaceutical Materials, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea.
Nguyen Minh DucCenter for Nutraceutical and Pharmaceutical Materials, Myongji University, Cheoin-gu, Gyeonggi-do, Republic of Korea.
Seungwha PaikDepartment of Microbiology, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Jin Ho ChoeDepartment of Microbiology, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Eun-Kyeong JoDepartment of Microbiology, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Chulhun L ChangDepartment of Laboratory Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
Jong Seok LeeInternational Tuberculosis Research Center, Changwon, Republic of Korea.
Birgit U JakiInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Guido F PauliInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Scott G FranzblauInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
Sanghyun ChoInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA jkcno1@uic.edu.
University of Illinois Chicago · USMyongji University · KRChungnam National University · KRInternational Tuberculosis Research Center · KRPusan National University Yangsan Hospital · KR
Funding
900MHz NMR for Structural Biology in ChicagoP41GM068944 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GETTINS, PETER G.W. · 2003 to 2007
$6.2MResearch Training in Natural Product Complementary and Integrative HealthT32AT007533 · NCCIH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Joanna E Burdette, JIMMY ORJALA · 2013 to 2026
$4.3MDevelopment of a transformative approach to the rapid detection, isolation, and iR21AI093919 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI JAKI, BIRGIT URSULA · 2012 to 2013
$401kNCCIH NIH HHS T32 AT007533NIAID NIH HHS R21 AI093919NIGMS NIH HHS P41 GM068944
Abstract
ClpC1 is an emerging new target for the treatment of
Indexed as
Antitubercular AgentsATP-Dependent ProteasesBacterial ProteinsMicrobial Sensitivity TestsMycobacterium abscessusMycobacterium Infections, NontuberculousMycobacterium tuberculosisOligopeptidesTuberculosis, PulmonaryAntitubercular AgentsATP-Dependent ProteasesBacterial ProteinsOligopeptidesrufomycinClpC1cyclic peptideMycobacterium abscessusMycobacterium tuberculosisrufomycin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.